PHILADELPHIA, PA, September 07, 2013 /24-7PressRelease/
-- The Burzynski Clinic is a leading cancer treatment center that focuses on using personalized targeted therapy to treat difficult types of cancer such as brain tumors. When tumors do not respond to chemotherapy or radiation, or those are not viable options, people often look for alternative forms of treatment. A recent article
in Healthline reveals encouraging treatment therapy that may help to destroy dangerous cancer cells. Professionals from the Burzynski Clinic weigh in on these new developments.
A new drug, TR100, may hold hope for treating cancer. Developed by researchers at the University of New South Wales (UNSW) in Australia, the drug targets the actual structure of the cells and destroys these proteins, essentially causing the cancer cell to self destruct. It does not destroy healthy cells, however. The two proteins, actin and myosin, give cells their structure. They are found throughout the body, including in the heart muscles. This is one reason why researchers have shied away from targeting these proteins with chemotherapy.
Dr. Peter Gunning, a world myosin specialist, has isolated the two specific types of myosin that cancer cells use but healthy cells do not. They are called tropomyosins. Along with Dr. Justine Stehn, a research fellow in the oncology research unit at the UNSW School of Medical Sciences, they created the drug TR100. "We've really gone after the core component of the internal scaffold or structure of the cancer cells," explains Dr. Stehn. "[When] the cell senses that there's something fundamentally wrong with its architecture, it will undergo programmed cell death." This means that the cell breaks down and is absorbed, recycled, and reused by other cells in the body.
However, in addition to cancer cells using this type of tropomyosin, stem cells do as well. Stem cells help in the generation of new cells, especially in developing embryos. The TR100 would target these cells after they have differentiated and become specific types of cells and are no longer growing. In the bone marrow and brain these cells remain active long after birth, so that is one area of concern when using TR100 as a treatment. Dr. Stehn notes that when the drug was tested in the lab on heart, liver, and brain cells, they were unharmed. It was also tested on neuroblastoma and melanoma and successfully killed the cancer cells while leaving healthy cells undamaged. This is a major step toward fighting cancer. Dr. Stehn is aiming for clinical trials to begin in 2015.
Professionals at the Burzynski Clinic are keeping their eye on these promising developments, but have some reservations. "Attacking the tropomyosins that cancer cells are using to build internal scaffolding of the cell is a promising approach," says a representative for the company. "It is difficult to predict, however, if the medications which destroy two tropomyosins in cancer cells will not interfere with memory processes in the brain. Interaction of some varieties of actin and myosin is necessary for the formation of new synapses and specific memory circuits. It is hoped that human trials will not result in neurodegeneration and impaired memory." The Burzynski Clinic is interested to see the results of future clinical trials.
The Burzynski Clinic was founded in 1977 by Stanislaw Burzynski, MD, PhD. It focuses on the use of personalized therapy to treat various forms of cancer. They identify the unique gene alterations related to cancer in each patient and formulate a personalized treatment plan.